[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse CAMK2B

Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Sarcoplasmic reticulum membrane Peripheral membrane protein Cytoplasmic side Cell junction, synapse Note=In slow-twitch muscle, evenly distributed between longitudinal SR and junctional SR.
Domain PF08332 Calcium/calmodulin dependent protein kinase II association domain
PF00069 Protein kinase domain
Function

Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in dendritic spine and synapse formation, neuronal plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in skeletal muscle. In neurons, plays an essential structural role in the reorganization of the actin cytoskeleton during plasticity by binding and bundling actin filaments in a kinase-independent manner. This structural function is required for correct targeting of CaMK2A, which acts downstream of NMDAR to promote dendritic spine and synapse formation and maintain synaptic plasticity which enables long-term potentiation (LTP) and hippocampus-dependent learning. In developing hippocampal neurons, promotes arborization of the dendritic tree and in mature neurons, promotes dendritic remodeling. Participates in the modulation of skeletal muscle function in response to exercise. In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport and in fast-twitch muscle participates in the control of Ca(2+) release from the SR through phosphorylation of triadin, a ryanodine receptor-coupling factor, and phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006816 calcium ion transport
GO:0009266 response to temperature stimulus
GO:0009408 response to heat
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010959 regulation of metal ion transport
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014733 regulation of skeletal muscle adaptation
GO:0014888 striated muscle adaptation
GO:0016358 dendrite development
GO:0021700 developmental maturation
GO:0022604 regulation of cell morphogenesis
GO:0031346 positive regulation of cell projection organization
GO:0034341 response to interferon-gamma
GO:0034605 cellular response to heat
GO:0043500 muscle adaptation
GO:0043501 skeletal muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0044057 regulation of system process
GO:0045666 positive regulation of neuron differentiation
GO:0046777 protein autophosphorylation
GO:0048167 regulation of synaptic plasticity
GO:0048168 regulation of neuronal synaptic plasticity
GO:0048169 regulation of long-term neuronal synaptic plasticity
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050769 positive regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050775 positive regulation of dendrite morphogenesis
GO:0050803 regulation of synapse structure or activity
GO:0050804 modulation of synaptic transmission
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0051823 regulation of synapse structural plasticity
GO:0051924 regulation of calcium ion transport
GO:0051962 positive regulation of nervous system development
GO:0060074 synapse maturation
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060996 dendritic spine development
GO:0060997 dendritic spine morphogenesis
GO:0060998 regulation of dendritic spine development
GO:0060999 positive regulation of dendritic spine development
GO:0061001 regulation of dendritic spine morphogenesis
GO:0061003 positive regulation of dendritic spine morphogenesis
GO:0070838 divalent metal ion transport
GO:0071346 cellular response to interferon-gamma
GO:0072511 divalent inorganic cation transport
GO:0090128 regulation of synapse maturation
GO:0090129 positive regulation of synapse maturation
GO:0090257 regulation of muscle system process
GO:0097061 dendritic spine organization
GO:1900006 positive regulation of dendrite development
GO:1900034 regulation of cellular response to heat
Molecular Function GO:0003779 actin binding
GO:0004674 protein serine/threonine kinase activity
GO:0004683 calmodulin-dependent protein kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005516 calmodulin binding
Cellular Component GO:0016528 sarcoplasm
GO:0016529 sarcoplasmic reticulum
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0033017 sarcoplasmic reticulum membrane
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04020 Calcium signaling pathway
hsa04024 cAMP signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04114 Oocyte meiosis
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04310 Wnt signaling pathway
hsa04360 Axon guidance
hsa04713 Circadian entrainment
hsa04720 Long-term potentiation
hsa04722 Neurotrophin signaling pathway
hsa04725 Cholinergic synapse
hsa04728 Dopaminergic synapse
hsa04740 Olfactory transduction
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04911 Insulin secretion
hsa04912 GnRH signaling pathway
hsa04916 Melanogenesis
hsa04921 Oxytocin signaling pathway
hsa04922 Glucagon signaling pathway
hsa04971 Gastric acid secretion
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events
R-HSA-422475: Axon guidance
R-HSA-442729: CREB phosphorylation through the activation of CaMKII
R-HSA-442742: CREB phosphorylation through the activation of Ras
R-HSA-5576891: Cardiac conduction
R-HSA-3371556: Cellular response to heat stress
R-HSA-2262752: Cellular responses to stress
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-3371571: HSF1-dependent transactivation
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-983712: Ion channel transport
R-HSA-5578775: Ion homeostasis
R-HSA-936837: Ion transport by P-type ATPases
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-397014: Muscle contraction
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-5576892: Phase 0 - rapid depolarisation
R-HSA-438064: Post NMDA receptor activation events
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-442982: Ras activation uopn Ca2+ infux through NMDA receptor
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-438066: Unblocking of NMDA receptor, glutamate binding and activation
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CAMK2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CAMK2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CAMK2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1050.668
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1780.682
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3170.41
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2030.672
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1240.911
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6160.639
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2690.693
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3430.737
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.8720.436
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.450.429
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.660.39
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.670.0169
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CAMK2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CAMK2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CAMK2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CAMK2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CAMK2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CAMK2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CAMK2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCAMK2B
Namecalcium/calmodulin-dependent protein kinase II beta
Aliases CAM2; CAMK2; CaM-kinase II beta chain; calcium/calmodulin-dependent protein kinase type II beta chain; CaM k ......
Chromosomal Location7p14.3-p14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CAMK2B collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CAMK2B.
ID Name Drug Type Targets #Targets
DB07168[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrileSmall MoleculeCAMK2B1